BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Altimmune readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Altimmune's drugs run\, from Clin
 icalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07009860-175@assetmemo.bio
DTSTAMP:20261121T005844Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:pemvidutide: Phase 2 readout est. (NCT07009860)
DESCRIPTION:pemvidutide\, phase 2.\nStudy: RESTORE TRIAL: Study of the Effi
 cacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Live
 r Disease (ALD)\nEstimated primary completion: 30 September 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/pemvidutide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07009860
URL:https://assetmemo.bio/drug/pemvidutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07795164-175@assetmemo.bio
DTSTAMP:20261121T005844Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:pemvidutide: Phase 3 readout est. (NCT07795164)
DESCRIPTION:pemvidutide\, phase 3\, MASH / NASH.\nStudy: Phase 3 Study of t
 he Efficacy\, Safety\, and Clinical Outcomes of Pemvidutide in MASH\nEstim
 ated primary completion: December 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pemvidutide#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07795164
URL:https://assetmemo.bio/drug/pemvidutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
